Broader Options for Experimental Clinical Research in Melanoma - Time for Adaptive Platform Trials?

NEJM Evid

Departments of Health Services, Policy, and Practice and Biostatistics, Brown University School of Public Health, Providence, RI.

Published: October 2024

Download full-text PDF

Source
http://dx.doi.org/10.1056/EVIDe2400284DOI Listing

Publication Analysis

Top Keywords

broader options
4
options experimental
4
experimental clinical
4
clinical melanoma
4
melanoma time
4
time adaptive
4
adaptive platform
4
platform trials?
4
broader
1
experimental
1

Similar Publications

Emerging carbapenem-resistant in a tertiary care hospital in Lima, Peru.

Microbiol Spectr

January 2025

Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

The emergence of carbapenem-resistant (CRKP) poses a significant public health threat, particularly in low- and middle-income countries (LMICs) with limited surveillance and treatment options. This study examines the genetic diversity, resistance patterns, and transmission dynamics of 66 CRKP isolates recovered over 5 years (2015-2019) after the first case of CRKP was identified at a tertiary care hospital in Lima, Peru. Our findings reveal a shift from to as the dominant carbapenemase gene after 2017.

View Article and Find Full Text PDF

Background: Colorectal obstruction is a critical condition requiring prompt diagnosis and intervention. Gastrografin, a water-soluble contrast agent, combines diagnostic and therapeutic benefits, facilitating bowel cleansing and enhancing intestinal motility. This study assessed the safety and effectiveness of Gastrografin enemas in emergency settings.

View Article and Find Full Text PDF

Background: Expanding access to equitable health insurance is an important lever towards the overall strategy for achieving universal health coverage. In Nigeria, health insurance coverage is low with a renewed government action on increasing access to and coverage of high-quality healthcare services to citizens, particularly for the vulnerable and poor population. Therefore, our study co-creates the priorities for expanding health insurance in Nigeria, focusing on key policy reforms, public advocacy, and innovative financing strategies to ensure broader and more equitable coverage for the population.

View Article and Find Full Text PDF

The TL1A inhibitors in IBD: what's in the pot?

Expert Rev Gastroenterol Hepatol

January 2025

IBD Center, Gastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy.

Introduction: Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), present ongoing challenges despite advances in pathophysiological understanding and therapeutic options. Current therapies often fail to achieve sustained remission, necessitating exploration of novel treatment targets.

Areas Covered: This review explores the role of Tumor Necrosis Factor-like cytokine 1A (TL1A) and its receptor DR3 in IBD pathogenesis, detailing their involvement in mucosal homeostasis and immune modulation.

View Article and Find Full Text PDF

Multiple myeloma (MM), the second most common hematologic malignancy in the United States, is characterized by repeated cycles of remission and relapse, with increasing resistance to treatment after each line of therapy. Despite the virtually incurable nature of MM, recent therapeutic breakthroughs have fundamentally reshaped its treatment landscape. This review explores evolving care paradigms, spanning from newly diagnosed MM to relapsed or refractory disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!